Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Inhaled Tiotropium on Spirometric Parameters in Patients with Tuberculous Destroyed Lung

  • Yum, Ho-Kee (Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine) ;
  • Park, I-Nae (Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine)
  • Received : 2014.04.22
  • Accepted : 2014.07.07
  • Published : 2014.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In Korea, patients with destroyed lung due to tuberculosis (TB) account for a significant portion of those affected by chronic pulmonary function impairment. The objective of our research was to evaluate the efficacy of inhaled tiotropium bromide in TB destroyed lung. Methods: We compared the effectiveness of inhaled tiotropium bromide for 2 months between pre- and post-treatment pulmonary function tests performed on 29 patients with destroyed lung due to TB. Results: The mean age of the total number of patients was $63{\pm}9$ years, where 15 patients were male. The pre-treatment mean forced expiratory volume in 1 second ($FEV_1$) was $1.02{\pm}0.31L$ ($44.1{\pm}16.0%$ predicted). The pre-treatment mean forced vital capacity (FVC) was $1.70{\pm}0.54L$ ($52.2{\pm}15.8%$ predicted). Overall, the change in $FEV_1%$ predicted over baseline with tiotropium was $19.5{\pm}19.1%$ (p<0.001). Twenty patients (72%) got better than a 10% increase in $FEV_1$ over baseline with tiotropium, but one patient showed more than a 10% decrease in $FEV_1$. Overall, the change in FVC% predicted over baseline with tiotropium was $18.5{\pm}19.9%$ (p<0.001). Seventeen patients (59%) experienced greater than a 10% increase in FVC over baseline with tiotropium; 12 (41%) patients had stable lung function. Conclusion: The inhaled tiotropium bromide therapy may lead to improve lung functions in patients with TB destroyed lung. However, the long-term effectiveness of this treatment still needs to be further assessed.

Keywords

References

  1. Kim HY, Song KS, Goo JM, Lee JS, Lee KS, Lim TH. Thoracic sequelae and complications of tuberculosis. Radiographics 2001;21:839-58. https://doi.org/10.1148/radiographics.21.4.g01jl06839
  2. Ramos LM, Sulmonett N, Ferreira CS, Henriques JF, de Miranda SS. Functional profile of patients with tuberculosis sequelae in a university hospital. J Bras Pneumol 2006;32:43-7. https://doi.org/10.1590/S1806-37132006000100010
  3. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA, Fresen JL, et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998;12:351-6. https://doi.org/10.1183/09031936.98.12020351
  4. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med 2003;97:1237-42. https://doi.org/10.1016/S0954-6111(03)00255-5
  5. Lam KB, Jiang CQ, Jordan RE, Miller MR, Zhang WS, Cheng KK, et al. Prior TB, smoking, and airflow obstruction: a crosssectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010;137:593-600. https://doi.org/10.1378/chest.09-1435
  6. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, et al. Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 2007;132:1591-8. https://doi.org/10.1378/chest.07-0755
  7. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. Chest 2007;131:1817-24. https://doi.org/10.1378/chest.06-2949
  8. Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest 1998;113:933-43. https://doi.org/10.1378/chest.113.4.933
  9. Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007;30:1180-5. https://doi.org/10.1183/09031936.00083507
  10. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989;83:195-8. https://doi.org/10.1016/S0954-6111(89)80031-9
  11. Snider GL, Doctor L, Demas TA, Shaw AR. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 1971;103:625-40.
  12. Saito Y, Azuma A, Morimoto T, Fujita K, Abe S, Motegi T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med 2008;47:585-91. https://doi.org/10.2169/internalmedicine.47.0568
  13. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995;8:1506-13.
  14. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46. https://doi.org/10.1183/09031936.04.00014304
  15. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2006. Geneva: World Health Organization; 2008.
  16. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64. https://doi.org/10.1164/ajrccm.161.2.ats3-00
  17. Chakrabarti B, Calverley PM, Davies PD. Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007;2:263-72.
  18. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006;61:259-66. https://doi.org/10.1136/thx.2005.051979
  19. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000;55:32-8. https://doi.org/10.1136/thorax.55.1.32
  20. Salorinne Y, Stenius-Aarniala B, Poppius H. Effect of ipratropium bromide and fenoterol on airway obstruction in chronic pulmonary tuberculosis. Respiration 1979;38:151-4. https://doi.org/10.1159/000194072

Cited by

  1. Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation vol.15, pp.None, 2014, https://doi.org/10.2147/tcrm.s194324
  2. Factors Associated with Indacaterol Response in Tuberculosis-Destroyed Lung with Airflow Limitation vol.82, pp.1, 2014, https://doi.org/10.4046/trd.2018.0050
  3. Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea vol.20, pp.None, 2014, https://doi.org/10.1186/s12931-019-1055-5
  4. Tiotropium Is Predicted to Be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis vol.12, pp.7, 2020, https://doi.org/10.3390/v12070776